Industry Insights

  1. AI-Powered Strategy Is Redefining Patient Recruitment Performance 9/9/2025

    This AI-powered platform is helping CROs and sponsors tackle the unsolved challenge they've faced for decades: clinical trials that launch late, recruit slowly, and miss enrollment targets.

  2. How Community-Based Research Models Expand Access 9/9/2025

    As momentum continues to grow in neurology research, how can community-based research models help overcome recruitment and retention challenges in complex areas like Alzheimer's?

  3. Are Pragmatic Trials The Patient Recruitment Solution We've Been Looking For? 9/9/2025

    TransCelerate's Rob DiCicco reintroduces the "pragmatic trial" design concept, discusses its potential benefits, and provides resources for its integration.

  4. The New FDA Era Of Radical Transparency And Pervasive Oversight 9/9/2025

    The first half of 2025 has been transformative for biopharmaceutical quality and regulatory affairs, with the FDA leading the charge with four significant changes. Curadian Group's David Grote discusses implications for all four.

  5. GLP-1 Ocular Safety Monitoring At Point-Of-Need 9/8/2025

    Regulators are sharpening their focus on ocular safety in GLP-1 receptor agonist trials following emerging evidence linking semaglutide to non-arteritic anterior ischemic optic neuropathy (NAION).

  6. Redesigning Oncology Trials Around Tumor Vulnerability: The Rise of WEE1 And DDR Strategies 9/8/2025

    As clinical progress with DNA damage response (DDR) continues to evolve, research must respond with adaptive models, smarter combinations, and biomarker-informed patient selection.

  7. Rethinking Clinical Development In The Age Of Synthetic Cell Therapy 9/5/2025

    Synthetic biology, especially when applied to engineered stem cells, such as induced mesenchymal stem cells (iMSCs), represents a new frontier. But to get these cells to patients, we need to reimagine how we develop and evaluate them.

  8. Why Scalable EDC Systems Matter In Global Pharmaceutical Trials 9/4/2025

    Sponsors who treat EDC as core infrastructure—not just software—are best positioned to succeed globally. Explore how EDC platforms keep studies compliant while enabling flexibility.

  9. How EDC Powers End-To-End Data Management In Pharma-Sponsored Clinical Trials 9/4/2025

    As clinical research moves toward adaptive, decentralized, and data-rich models, EDC remains the backbone that makes innovation operationally feasible.

  10. Oversight Monitoring In Clinical Trials 9/3/2025

    By engaging early and aligning oversight practices with inspection readiness goals, organizations can protect trial integrity, shorten development timelines, and reinforce patient safety.